title: Comparison of two dosages of recombinant human follicle-stimulating hormone in Chinese women undergoing controlled ovarian stimulation: prospective randomised double-blind study.
abstract: OBJECTIVE
  To compare two dosages of recombinant human follicle-stimulating hormone for controlled ovarian stimulation.
  
  
  METHODS
  Prospective, randomised double-blind study.
  
  
  METHODS
  Tertiary assisted reproduction unit, Hong Kong.
  
  
  METHODS
  Forty subfertile Chinese women aged 24 to 38 years undergoing in vitro fertilisation. Entry criteria included good physical and mental health, and a body mass index between 18 and 29 kg/m2. Exclusion criteria were subfertility caused by an endocrine abnormality, polycystic ovarian syndrome, or absent ovarian function; previous assisted reproduction treatment in which fewer than three oocytes were retrieved; prior hospitalisation due to severe ovarian hyperstimulation syndrome; chronic cardiovascular, hepatic, renal, or pulmonary disease; alcohol or drug abuse; and the administration of investigational drugs within the previous 3 months.
  
  
  METHODS
  Injection of recombinant follicle-stimulating hormone, 100 IU/d or 200 IU/d.
  
  
  METHODS
  The number of oocytes, total dose of drug used, and pregnancy rates.
  
  
  RESULTS
  Compared with the 20 women receiving 200 IU/d, the 20 who received 100 IU/d had a significantly lower median number of oocytes retrieved and median total dose of drug used (7.5 versus 15.0 [P<0.001] and 1200 IU versus 2000 IU [P<0.001], respectively). The pregnancy rates in the fresh cycles were similar (20%) in both groups, but the cumulative pregnancy rates in the 100 IU/d and 200 IU/d groups were 20.0% and 45.0% per stimulated cycle, respectively. The incidence of ovarian hyperstimulation syndrome in the 100 IU/d and 200 IU/d groups was 5.0% and 20.0%, respectively.
  
  
  CONCLUSIONS
  Use of 100 IU/d of recombinant follicle-stimulating hormone requires a lower total dose but results in the harvest of half the number of oocytes compared with when a dosage of 200 IU/d is used.
authors.affiliation: Department of Obstetrics and Gynaecology, The University of Hong Kong, Queen Mary Hospital, Pokfulam, Hong Kong.
authors.forename: E Y
authors.initials: EY
authors.lastname: Ng
authors.forename: W S
authors.initials: WS
authors.lastname: Yeung
authors.forename: P C
authors.initials: PC
authors.lastname: Ho
mesh_terms: D000328:Adult; D015992:Body Mass Index; D002681:China; D004311:Double-Blind Method; D005260:Female; D005307:Fertilization in Vitro / Q000379:methods; D005640:Follicle Stimulating Hormone / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007247:Infertility, Female; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced; D010062:Ovulation Induction / Q000379:methods*; D011247:Pregnancy; D018873:Pregnancy Rate; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D011994:Recombinant Proteins; D005640:Follicle Stimulating Hormone